Allergan Plc – Product Pipeline Review

Global Markets Direct’s, ‘Allergan Plc – Product Pipeline Review – 2016’, provides an overview of the Allergan Plc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Allergan Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Allergan Plc

The report provides overview of Allergan Plc including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Allergan Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Allergan Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Allergan Plc’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Allergan Plc

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Allergan Plc’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Allergan Plc Snapshot 8

Allergan Plc Overview 8

Key Information 8

Key Facts 8

Allergan Plc - Research and Development Overview 9

Key Therapeutic Areas 9

Allergan Plc - Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products - Monotherapy 14

Pipeline Products - Combination Treatment Modalities 15

Pipeline Products - Partnered Products 16

Partnered Products/Combination Treatment Modalities 17

Pipeline Products - Out-Licensed Products 19

Out-Licensed Products/Combination Treatment Modalities 20

Allergan Plc - Pipeline Products Glance 21

Allergan Plc - Late Stage Pipeline Products 21

Pre-Registration Products/Combination Treatment Modalities 21

Filing rejected/Withdrawn Products/Combination Treatment Modalities 22

Phase III Products/Combination Treatment Modalities 23

Allergan Plc - Clinical Stage Pipeline Products 24

Phase II Products/Combination Treatment Modalities 24

Phase I Products/Combination Treatment Modalities 25

Allergan Plc - Early Stage Pipeline Products 26

IND/CTA Filed Products/Combination Treatment Modalities 26

Preclinical Products/Combination Treatment Modalities 27

Discovery Products/Combination Treatment Modalities 28

Allergan Plc - Drug Profiles 29

eluxadoline 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

(nebivolol + valsartan) 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

dihydroergotamine mesylate 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

norethindrone 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

abicipar pegol 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Aczone X 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

AGN-229666 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

bimatoprost SR 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

cariprazine 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

dalbavancin 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

desmopressin acetate 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

onabotulinumtoxin A 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

oxymetazoline hydrochloride 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

sarecycline hydrochloride 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

ulipristal acetate 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

AGN-195263 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

AGN-223575 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

ANT-1207 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

ANT-1403 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

brimonidine tartrate implant 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

cyclosporine 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

lidocaine hydrochloride 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

NRX-1074 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

oxybutynin chloride 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

rapastinel 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

ubrogepant 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

udenafil 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

AGN-232411 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

MK-8031 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

bezafibrate ER 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

setipiprant 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

AGN-151200 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Small Molecule for Glaucoma 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Neurotoxin Program 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Recombinant Proteins for Ophthalmology 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Small Molecules to Inhibit CGRP Receptor for Migraine 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Allergan Plc - Pipeline Analysis 82

Allergan Plc - Pipeline Products by Target 82

Allergan Plc - Pipeline Products by Route of Administration 85

Allergan Plc - Pipeline Products by Molecule Type 86

Allergan Plc - Pipeline Products by Mechanism of Action 87

Allergan Plc - Recent Pipeline Updates 90

Allergan Plc - Dormant Projects 132

Allergan Plc - Discontinued Pipeline Products 135

Discontinued Pipeline Product Profiles 135

alvameline maleate 135

dapoxetine hydrochloride 135

dexamethasone acetate 135

dexloxiglumide 136

ME-1036 136

memantine hydrochloride 136

neramexane mesylate 136

NRX-1050 136

NRX-20xx 136

onabotulinumtoxin A 137

radiprodil 137

Allergan Plc - Company Statement 138

Allergan Plc - Locations And Subsidiaries 140

Head Office 140

Other Locations & Subsidiaries 140

Appendix 149

Methodology 149

Coverage 149

Secondary Research 149

Primary Research 149

Expert Panel Validation 149

Contact Us 149

Disclaimer 150

List of Tables

List of Tables

Allergan Plc, Key Information 8

Allergan Plc, Key Facts 8

Allergan Plc – Pipeline by Indication, 2016 10

Allergan Plc – Pipeline by Stage of Development, 2016 13

Allergan Plc – Monotherapy Products in Pipeline, 2016 14

Allergan Plc – Combination Treatment Modalities in Pipeline, 2016 15

Allergan Plc – Partnered Products in Pipeline, 2016 16

Allergan Plc – Partnered Products/ Combination Treatment Modalities, 2016 17

Allergan Plc – Out-Licensed Products in Pipeline, 2016 19

Allergan Plc – Out-Licensed Products/ Combination Treatment Modalities, 2016 20

Allergan Plc – Pre-Registration, 2016 21

Allergan Plc – Filing rejected/Withdrawn, 2016 22

Allergan Plc – Phase III, 2016 23

Allergan Plc – Phase II, 2016 24

Allergan Plc – Phase I, 2016 25

Allergan Plc – IND/CTA Filed, 2016 26

Allergan Plc – Preclinical, 2016 27

Allergan Plc – Discovery, 2016 28

Allergan Plc – Pipeline by Target, 2016 82

Allergan Plc – Pipeline by Route of Administration, 2016 85

Allergan Plc – Pipeline by Molecule Type, 2016 86

Allergan Plc – Pipeline Products by Mechanism of Action, 2016 87

Allergan Plc – Recent Pipeline Updates, 2016 90

Allergan Plc – Dormant Developmental Projects,2016 132

Allergan Plc – Discontinued Pipeline Products, 2016 135

Allergan Plc, Subsidiaries 140

List of Figures

List of Figures

Allergan Plc – Pipeline by Top 10 Indication, 2016 10

Allergan Plc – Pipeline by Stage of Development, 2016 13

Allergan Plc – Monotherapy Products in Pipeline, 2016 14

Allergan Plc – Partnered Products in Pipeline, 2016 16

Allergan Plc – Out-Licensed Products in Pipeline, 2016 19

Allergan Plc – Pipeline by Top 10 Target, 2016 82

Allergan Plc – Pipeline by Top 10 Route of Administration, 2016 85

Allergan Plc – Pipeline by Molecule Type, 2016 86

Allergan Plc – Pipeline Products by Top 10 Mechanism of Action, 2016 87

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared